Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.32 0.28 (1.27%) Market Cap: 1.61 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 58/100

Q3 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Nov 01, 2022 / 12:30PM GMT
Release Date Price: $12.8 (+12.08%)
Operator

Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals third quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank
Kiniksa Pharmaceuticals, Ltd. - Associate Director of IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our third quarter 2022 financial results and corporate update. A press release highlighting these results can be found on our website under the Investors & Media section.

As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. John Paolini, our Chief Medical Officer, will provide a clinical update; Ross Moat, our Chief Commercial Officer, will provide an update on our ARCALYST commercial execution. Then, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2022 financial results. And finally, Sanj will return for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot